How Healthy Changes Can
Reduce Triglyceride (TG) Levels


Lower Your TGs and Improve Your Lipid Profile1

Your healthcare professional can advise you on how to make healthy changes

There are many things you can do to help bring down high TGs. Your healthcare professional can help you put together a plan that may include some or all of the following:

  • Improving your diet: Reducing saturated fats (found in meats and full-fat dairy products) is a good place to begin. You may also need to cut back on excess sugar, which the body converts into fats.
  • Reduce alcohol consumption: Alcohol can increase TG levels.
  • Getting more exercise: Talk to your healthcare professional about getting started on an exercise program. Healthy muscles increase “good” (HDL) cholesterol.
  • Lose weight: If you improve your diet and get more exercise, chances are you also will lose weight too. Losing fat around your midsection can help improve TG levels.
  • Improve glucose control: If you have type 2 diabetes (a chronic disease characterized by too much glucose [sugar] in the blood), the same diet and exercise tips that help reduce high TG levels can help you improve glucose control.
  • Take prescription medications as directed: If diet and exercise are not enough to reach your goals, you may need a prescription medication. Be sure to take your medication every day, as directed by your doctor.


Reference: 1. National Cholesterol Education Program (NCEP). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluations, and Treatment of High Blood Cholesterol in Adults. (Adult Treatment Panel III—Final Report. NIH Publication No.02-5215. September 2002.

   

INDICATIONS

Primary Hypercholesterolemia and Mixed Dyslipidemia: ANTARA® is indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG), and apolipoprotein B (Apo B), and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia.

Hypertriglyceridemia: ANTARA® is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (eg, >2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.

Important limitations of use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus.

IMPORTANT SAFETY INFORMATION

ANTARA® is contraindicated in patients with severe renal impairment; active liver disease, including unexplained persistent liver function abnormalities; preexisting gallbladder disease; nursing mothers; and hypersensitivity to fenofibric acid, choline fenofibrate or fenofibrate.

The effect of ANTARA® on coronary heart disease morbidity and mortality and non-cardiovascular mortality has not been established.

Fibrates increase the risk for myopathy and are associated with rhabdomyolysis. The risks for myopathy and rhabdomyolysis are increased when fibrates are co-administered with a statin, particularly in the elderly and in patients with diabetes, renal failure, or hypothyroidism. The combined use of fibrates and statins should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk.

Patients should be advised to report promptly unexplained muscle pain, tenderness, or weakness. Discontinue ANTARA® if myopathy/myositis is suspected or diagnosed or if CPK levels are markedly elevated.

Fenofibrate at doses equivalent to 90 mg ANTARA® per day can increase serum transaminases. Monitor liver function regularly and discontinue treatment if enzyme levels persist above 3 times the normal limit.

Fenofibrate can reversibly elevate serum creatinine. Monitor renal function in patients with renal impairment.

Fenofibrate may lead to cholelithiasis. Discontinue ANTARA® if gallstones are found.

ANTARA® can potentiate the activity of oral anticoagulants. Monitoring and dosage adjustment of anticoagulants as needed are recommended.

Other precautions include pancreatitis, hematologic changes, hypersensitivity reactions, and venothromboembolic events.

The most common adverse reactions (>2% and ≥1% greater than placebo) are abnormal liver function tests, increased AST, increased ALT, increased CPK, and rhinitis.

This Web site and the information contained herein is intended for use by US residents only.